Cutaneous immune-related adverse events: incidence rates, risk factors and association with extracutaneous toxicity - a prospective study of 189 patients treated with checkpoint inhibitors at a Spanish tertiary care hospital.

Autor:	Juan-Carpena G; Department of Dermatology, Morales Meseguer University Hospital, Murcia, Spain.; Toxirel Investigation Group, Alicante, Spain., Martínez-Banaclocha N; Toxirel Investigation Group, Alicante, Spain.; Department of Oncology, Dr. Balmis University General Hospital, Alicante, Spain.; Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain., Palazón-Cabanes JC; Department of Dermatology, 12 de Octubre University Hospital, Madrid, Spain., Niveiro-de Jaime M; Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.; Department of Pathology, Dr. Balmis University General Hospital, Alicante, Spain., Betlloch-Mas I; Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.; Dermatology, Dr. Balmis University General Hospital, Alicante, Spain.; Miguel Hernández University of Elche, Alicante, Spain., Blanes-Martínez M; Toxirel Investigation Group, Alicante, Spain.; Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.; Dermatology, Dr. Balmis University General Hospital, Alicante, Spain.
Jazyk:	angličtina
Zdroj:	Clinical and experimental dermatology [Clin Exp Dermatol] 2024 Aug 22; Vol. 49 (9), pp. 991-1001.
DOI:	10.1093/ced/llae060
Abstrakt:	Background: Clinicians are increasingly prescribing immune checkpoint inhibitors (ICIs) to treat cancer, but the real-world incidence, characteristics and risk factors of cutaneous immune-related adverse events (cirAEs) are unclear. Objectives: To determine the incidence, features and risk factors of cirAEs and to measure their possible association with extracutaneous toxicity. Methods: We conducted a prospective observational study in a Spanish tertiary care hospital, including people who started an ICI between March 2020 and May 2022. We used a survival analysis and a log-rank test to obtain and compare incidence rates, and a multivariate Cox model to detect risk factors for cirAEs. Results: We included 189 patients, 82 (43.4%) of whom presented cutaneous toxicity. The incidence of cirAEs was 75.0 per 100 person-years, with a 50.0% probability of the appearance of a cirAE at 10 months of follow-up. The most frequent cirAE category was inflammatory dermatoses, and the most frequent types were pruritus, eczema and maculopapular eruptions. ICI combination therapy, a family history of psoriasis and rheumatological and pulmonary immune-related adverse events increased the risk of cirAEs. Conclusions: We found a high incidence of cirAEs, and they occurred early in the follow-up period. Dermatologists should be involved in the management of cirAEs, especially in people with risk factors. Competing Interests: Conflicts of interest The authors declare no conflicts of interest. (© The Author(s) 2024. Published by Oxford University Press on behalf of British Association of Dermatologists. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu